Use of guideline-recommended therapies for heart failure in the Medicare population.

Clinical Cardiology
Lisa D DiMartinoLesley H Curtis

Abstract

Most information about the use of guideline-recommended therapies for heart failure reflects what occurred at discharge after an inpatient stay. Using a nationally representative, community-dwelling sample of elderly Medicare beneficiaries, we examined how the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers has changed and factors associated with their use. Using data from the Medicare Current Beneficiary Survey cost and use files matched with Medicare claims data, we identified beneficiaries for whom a diagnosis of heart failure was reported between January 1, 2000, and December 31, 2004. Data on medications prescribed during the year of cohort entry were based on patient self-report. We used multivariable logistic regression to explore relationships between the use of ACE inhibitors/ARBs and beta-blockers and patient demographic characteristics. From 2000 through 2004, the use of ARBs increased from 12% to 19%, and the use of beta-blockers increased from 30% to 41%. The use of ACE inhibitors remained constant at 45%. Beneficiaries who reported having prescription drug insurance coverage were 32% more likely than other beneficiaries to have filled a prescription fo...Continue Reading

References

Oct 4, 2000·JAMA : the Journal of the American Medical Association·S F JencksD R Arday
Oct 12, 2001·JAMA : the Journal of the American Medical Association·A D FedermanJ Z Ayanian
Mar 21, 2002·Journal of General Internal Medicine·M A SteinmanK E Covinsky
Jun 3, 2004·Journal of the American College of Cardiology·Javed ButlerMarie R Griffin
Nov 1, 2005·The American Journal of Geriatric Pharmacotherapy·Sachin Kamal-BahlMark H Beers
Sep 22, 2007·The American Journal of Cardiology·Soko SetoguchiWolfgang C Winkelmayer
Feb 27, 2008·Archives of Internal Medicine·Lesley H CurtisKevin A Schulman
Sep 6, 2008·Journal of the American Geriatrics Society·Jennifer Tjia, Becky A Briesacher
Oct 29, 2008·Pharmacoepidemiology and Drug Safety·Niteesh K ChoudhryWilliam H Shrank
Dec 10, 2008·Archives of Internal Medicine·Judith M KramerKevin J Anstrom
Dec 10, 2008·Archives of Internal Medicine·Lesley H CurtisAdrian F Hernandez
Jan 28, 2009·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee

❮ Previous
Next ❯

Citations

Jul 3, 2013·Heart Failure Clinics·Mitchell A Psotka, John R Teerlink
Aug 4, 2012·Journal of Cardiac Failure·Gideon Y SteinShmuel Fuchs
Apr 13, 2011·The American Journal of Cardiology·Mori J KrantzUNKNOWN Get With the Guidelines Steering Committee and Hospitals
Sep 13, 2013·Journal of the American Heart Association·Zubin J EapenLesley H Curtis
Jul 28, 2012·Circulation·Nathaniel M HawkinsSimon Capewell
Apr 20, 2018·Current Treatment Options in Cardiovascular Medicine·Abhinav SoodW H Wilson Tang
Nov 29, 2017·Cardiovascular Drugs and Therapy·Emily B LevitanMonika M Safford
Jan 19, 2020·Research in Social & Administrative Pharmacy : RSAP·Blake Tyler McGeeJaved Butler
May 6, 2021·Journal of General Internal Medicine·John A StaplesJason M Sutherland
Jul 3, 2021·Journal of the American Heart Association·Amber E JohnsonJared W Magnani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.